Cannvas MedTech (CSE:MTEC)(Frankfurt: 3CM) (OTCPK: CANVF), a leading digital cannabis education and analytics company, is pleased to name a leading U.S.-based cannabis educator and industry consultant to its newly-formed Cannabis Sciences Advisory Board. Emma Chasen will join the Board to provide educational content focused on the science of cannabis, leveraging her academic training in plant chemistry and experience working with leading cannabis brands in developing educational programs for staff and customers.

“Emma brings an infectious energy and enthusiasm to the idea of cannabis education, along with a solid foundation of evidence-based knowledge and an unquenchable thirst to continue learning and sharing,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “We look forward to working with Emma and leaning on her expertise in cannabis sciences to continue providing our community with free and unbiased cannabis education from leading authorities in the field, going above and beyond the basics to allow Canadians access to a rich trove of information helping them make better decisions about their health and wellness.”


Ms. Chasen has had formal academic training in studying plant chemistry and secondary compounds, terpenes, alkaloids and cannabinoids, earning a specialized Biology degree with a focus on Medicinal Plant Research from Brown University. During her time as Director of Education at the award-winning Portland dispensary Farma, Ms. Chasen championed an evidence-based approach to cannabis education for consumers looking for alternative treatments, focusing on the plant’s genetic and chemical makeup instead of standard binary classifications.

“The addition of Emma Chasen to our Cannabis Sciences Advisory Board emphasizes the attention we expect to be paid to the scientific aspects of cannabis, from identification to usage, as a growing body of research continues to accumulate,” said Daniel Davidzon, Director of Strategy and Education, Cannvas MedTech Inc. “Emma’s experience creating educational cannabis curricula is essential to offering Cannvas.Me users accurate and timely evidence-based information, positioning the platform to better adapt to new discoveries as the science of cannabis catches up to the rest of the industry.”

Through her dedication to the science of cannabis, Ms. Chasen’s work has been featured in Newsweek, Forbes, High Times Magazine, The Oregon Leaf, Teen Vogue and many more publications lauding her approach to cannabis education.

As co-owner and operator of Portland-based Eminent Consulting, Ms. Chasen oversees the creation and execution of educational training programs for cannabis industry professionals and enthusiasts. She has stated her mission in the cannabis industry is to educate people on the science of cannabis and provide them with accessible and meaningful information so they can feel empowered to take charge of their own health care experience.

The Cannabis Sciences Advisory Board is an independent panel of esteemed and established scientific consultants from across a range of industries providing oversight and original content to the Cannvas.Me digital cannabis education platform. Operating independent of any licenced producers or clinics, Cannvas.Me works with its Medical Advisory Board and Educational Advisory Panel and newly-formed Cannabis Sciences Advisory Board to provide a safe space for cannabis education with no pressure to purchase or consume.

The Cannabis Sciences Advisory Board consists of prominent Canadians and Americans who are among the leaders in their fields with robust backgrounds in education, health sciences, medicine and research. Members of the Board will be in constant communication with the Cannvas.Me team to offer guidance on new educational modules, oversight of and contributions to original Cannvas.Me content, and insights into health sciences, clinical trials, medical and scientific regulatory affairs, and other related topics. Earlier this year, Cannvas appointed Angela Smith, PhD, as the Board lead.

About Cannvas MedTech Inc.
Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

For further information: ir@cannvasmedtech.com or visit cannvasmedtech.com

Related Links

https://cannvasmedtech.com

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 

Source: www.newswire.ca

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less